Webinar | November 7, 2022

The Strategic And Scientific Imperative For Prospectively Generated Real-World Evidence

Source: Worldwide Clinical Trials

Data characterizing the real-world clinical, economic, and humanistic impact of innovative medical products are increasingly used across the broad spectrum of clinical and commercial development to support both regulatory approval and market access (with the former being a relatively new phenomenon since implementation of the 21st Century Cures Act).  Although there are an increasing number of sources of high-quality RWD, there remain many situations in which a data-based solution has important strategic and/or scientific limitations.  This webinar will explore the RWE/RWD landscape and focus on those situations in which a prospective observational study or registry presents a more optimal solution, while also focusing on the unique operational factors that must be accommodated to maximize time- and cost-efficiency in the de novo generation of RWE.

VIEW THE WEBINAR!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Clinical Leader